Jordt Raymond M 4

What Happened

• Raymond M. Jordt, Chief Business Officer of Altimmune (ALT), had 15,850 restricted stock units (RSUs) convert to common shares on January 27, 2026 (reported as derivative exercise/conversion, code M).
• Of those shares, 4,229 were surrendered to the company to cover tax withholding at $6.18 per share, totaling $26,135 (reported under code F). Net shares retained by Jordt after withholding: 11,621 (15,850 - 4,229).
• This was a routine RSU vesting/settlement event (not an open-market purchase or sale).

Key Details

• Transaction date: 2026-01-27; Filing date: 2026-01-29 (timely).
• Reported items: 15,850 shares acquired via exercise/conversion of RSUs at $0.00; 4,229 shares disposed/surrendered for tax withholding at $6.18/share ($26,135).
• Net new shares retained: 11,621.
• Footnotes: F1—each RSU converts to one share when vested; F2—shares surrendered solely to cover taxes; F3—these RSUs vest in substantially equal annual installments over 4 years beginning Jan 27, 2025 and have no expiration.
• Filing timeliness: No late filing indicated.

Context

• This was a vesting/settlement of RSUs (conversion of a derivative), not an open-market sale or purchase. The surrender of shares to cover taxes is a common, administrative action and does not necessarily reflect a change in insider sentiment.
• Because the transaction was a conversion/vesting with share-withholding for taxes, there was no cash outlay to acquire the shares and no public sale of shares beyond the tax-withholding surrender.